A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment

Phase 1 Recruiting 16 enrolled Incyte Corporation

RandomizedParallel-groupOpen-labelTreatment

Summary

This study will be conducted to assess the safety and pharmacokinetics of INCB123667 when administered orally to adult participants with moderate or severe hepatic impairment.

Timeline

Start: 2026-05-27
Primary completion: 2027-04-13
Completion: 2027-04-13

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	INCB123667	Unknown	—	Oral

A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment

Summary

Timeline

Drugs

Indications